Impact of Amino Acids to Enhance Anabolism After Home-based Exercise

Exercise Clinical Trial

— B2B  

Official title:

Impact of Amino Acids to Enhance Anabolism After Home-based Exercise

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04850820
• Other study ID #: B2B
• Status: Completed
• Phase: N/A
• Start date: April 1, 2021
• Est. completion date: December 31, 2021

Study information

• Verified date: April 2022
• Source: University of Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An adequate quantity of lean body mass is vital for optimal health and performance, and is accrued when net protein balance (NPB) is positive. Amino acids are the building blocks of protein, and when consumed following resistance exercise, significantly improve NPB.

However, no study has investigated how a supplement of all of the essential amino acids (EAA) affects NPB following resistance exercise in a free-living, home-based setting, particularly when compared to a supplement of branched-chain amino acids (BCAA).

Therefore, the purpose of this study is to determine the impact of a novel EAA supplement on anabolism (e.g., NPB) as compared to BCAA and placebo supplements following home-based resistance exercise.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Aged 18-35 years

• Recreationally active; currently performing structured exercise (e.g., running, weight lifting, team-sport activity) at least 2 days per week

Exclusion Criteria:

• Body Mass Index: >29.9kg/m^2

• Inability to perform physical activity as determined by the Physical Activity Readiness Questionnaire

• Inability to adhere to protocol guidelines (e.g., alcohol, habitual diet)

• Regular tobacco use

• Illicit drug use (e.g., growth hormone, testosterone)

• Diagnosed medical condition under the care of a physician

• Inability to abstain from supplements (e.g., protein, creatine, HMB, BCAA, phosphatidic acid) at least three weeks before and during trials

• Individuals on any medications known to affect protein metabolism (e.g., corticosteroids, non-steroidal anti-inflammatories, or prescription-strength acne medications)

Related Conditions & MeSH terms

• Amino Acids, Essential
• Exercise
• Metabolism

Intervention

Dietary Supplement:
• Novel essential amino acid supplementation
This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
• Branched-chain amino acid supplementation (BCAA)
This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
• Isocaloric carbohydrate supplementation
This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.

Locations

Country	Name	City	State
Canada	Goldring Centre for High Performance Sport	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University of Toronto	Iovate Health Sciences International Inc

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Whole-body net leucine balance (umol/kg)	Used as a proxy of whole-body protein balance, and estimated by using [13C]leucine ingestion and breath/urine sample collection	5 hours/trial (four trials total)
Secondary	Urinary 3-methylhistidine (3-methylhistidine:creatinine ratio)	Used as a marker of muscle protein breakdown by measuring the 3-methylhistidine:creatinine ratio in the urine	5 hours/trial (four trials total)